Novo Nordisk just warned that sales could fall by 13% in 2026, sending its stock crashing nearly 20%. The culprit?…
Novo Nordisk shares have surged on the back of its groundbreaking oral Wegovy approval, making it the first company to…
Novo Nordisk offers Wegovy weight-loss pill in the US at $149 per month for self-pay patients, expanding access to oral…
Novo Nordisk shares surged nearly 9% in a single session after a key regulatory development in the US. The move…
Novo Nordisk’s US medical lead, Dr Jason Brett, told CNN that the pill is expected to give patients more choices…
Vikrant Shrotriya, Novo Nordisk India MD responds to questions on future pricing, generics competition post patent expiry in March, Indian-specific…
The class of GLP-1 agonist medications act by lowering the appetite with applications way beyond diabetes. These medicines will be…
Danish drugmaker Novo Nordisk has brought its popular weight loss drug Ozempic to India. Check out prices for all doses.
” We are doing $1-2 million run rate revenue in the US. We expect the US business to be larger…
Novo Nordisk shares plunge after semaglutide Alzheimer’s trial fails to meet its main goal, deepening pressure amid competition, leadership shifts…
This collaboration combines Novo Nordisk’s innovation in GLP-1 therapies with Emcure’s marketing and distribution strengths to improve access to obesity…
Novo Nordisk and Emcure Pharma team up to bring Poviztra, a new weight loss injection, to India. Learn more about…
Layoffs 2025: The job cuts follow similar moves by Oracle, Microsoft, and other companies that have recently let go of…
Ozempic faces over 1,800 lawsuits in US courts, with damages possibly topping $2 billion. Patients allege the drug caused stomach…
Wegovy, a weekly weight-loss injection by Novo Nordisk, has launched in India. Priced from Rs 17,000/month, it helps users lose…
Novo Nordisk is planning a major India launch of its blockbuster weight-loss drug Wegovy, aiming for Rs 8,600 crore in…
Despite the promising results, further research is needed before GLP-1 receptor agonists and dual GIP/GLP-1 receptor agonists can be integrated…
Martin Holst Lange, Executive Vice President, Development, Novo Nordisk, highlighted during the press briefing that their purpose is to address…